

Review on Advance Methods Used in Treatment of Cancer

Himanshu B. Borase¹, Juned Pinjari², Harshal K. Chaudhari³, Kanchan S. Akhare⁴

Student, Department of Pharmacy, P.G. College of Pharmaceutical Science and Research, Nandurbar, Maharashtra¹
Assist. Professor, Department of Pharmacy, P.G. College of Pharmaceutical Science and Research, Nandurbar, India²
Sr. Clinical Data Associate, Syneoshealth, Pune, India³
Sr. Process Associate, TCS, Pune, India⁴

Abstract: *Cancer is one of the most dreaded diseases of the 20th century and spreading further with continuance and increasing incidence in the 21st century. The situation is so alarming that every fourth person is having a lifetime risk of cancer. India registers more than 11 lakh new cases of cancer Every year, whereas, this figure is above 14 million worldwide. Is cancer curable? The short answer to this question is "Yes." In fact, all cancers Are curable if they are caught early enough. Cancer cells continue to grow unless one of four things occur:*

- (1) *The cancerous mass is removed Surgically;*
- (2) *using chemotherapy or another type of cancer -specific medication, such as hormonal therapy;*
- (3) *using radiation therapy;*
- (4) *The Cancer cells shrink and disappear on their own.*

Keywords: Cancer, Oncogenes, causes , Treatment ,Viral infection

REFERENCES

- [1]. Gorga F. (1998). The Molecular Basis of Cancer. Bridgewater Rev, 17(2):3–6.
- [2]. McCann J, Choi E, Yamasaki E, Ames BN. (1975). Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci U S A, 72(12):5135–9. [PMC free article] [PubMed].
- [3]. Perry AR. (2001). Oncogenes. Van Nostrand's Scientific Encyclopedia. eLS.
- [4]. Croce CM. (2008). Oncogenes and cancer. N Engl J Med, 358:502–11. [PubMed].
- [5]. Pierotti MA, Sozzi G, Croce CM. (2003). Mechanisms of oncogene activation. Kufe DW, Pollock RE, Weichselbaum RR, et al. Holland-Frei Cancer Med, 6th. 2003.
- [6]. Şevik M. (2012). Oncogenic viruses and mechanisms of oncogenesis. Turk J Vet Anim Sci, 36(4):323–9.
- [7]. Javed S, Ali M, Ali F, Anwar SS, Wajid N. (2015). Status of oxidative stress in breast cancer patients in Pakistani population. Adv Life Sci, 2(3):115–8.
- [8]. Luo J, Solimini NL, Elledge SJ. (2009). Principles of cancer therapy: oncogene and nononcogene addiction. Cell, 136(5):823–37. [PMC free article] [PubMed].
- [9]. Diamandis EP. (1992). Oncogenes and tumor suppressor genes: new biochemical tests. Crit Rev Clin Lab Sci, 29(3–4):269–305. [PubMed].
- [10]. Park BH, Vogelstein B. (2003). Tumor-suppressor genes. Cancer Med, 6:87–102.
- [11]. Englert C, Hou X, Maheswaran S, et al. (1995). WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J, 14(19):4662–75. [PMC free article] [PubMed].
- [12]. Soussi T. (2000). The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci, 910:121–37. [PubMed].
- [13]. Diamandis EP. (1997). Clinical applications of tumor suppressor genes and oncogenes in cancer. Clin Chim Acta, 257(2):157–80. [PubMed].
- [14]. Ahmed T, Ahmed RS, Basharat MU, et al. (2013). Comparative study to access coagulation abnormalities in breast cancer. Adv Life Sci. 1(2):96–103.

- [15]. Lopez-Chavez A, Thomas A, Rajan A, et al. (2015). Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. *J Clin Oncol*, 33(9):1000–7. [PMC free article] [PubMed].
- [16]. Khan MT, Afzal S, Rehman AU, Zeb T. (2015). Interleukin 10 (IL-10) promoter-1082 A> G polymorphism and risk of cancer: Meta-analysis. *Adv Life Sci*, 2(2):67–73.
- [17]. Sudhakar A. (2009). History of cancer, ancient and modern treatment methods. *J Cancer Sci Ther*, 1(2):1–4. [PubMed].
- [18]. Ottolino-Perry K, Diallo J-S, Lichty BD, Bell JC, McCart JA. (2010). Intelligent design: combination therapy with oncolytic viruses. *Mol Ther*, 18(2):251–63. [PMC free article] [PubMed].
- [19]. Barquinero J, Eixarch H, Perez-Melgosa M. (2004). Retroviral vectors: new applications for an old tool. *Gene Ther*, 11 Suppl 1:S3–9. [PubMed].
- [20]. Solly SK, Trajcevski S, Frisén C, et al. (2003). Replicative retroviral vectors for cancer gene therapy. *Cancer Gene Ther*, 10(1):30–9.
- [21]. Mikkers H, Berns A. (2003). Retroviral insertional mutagenesis: tagging cancer pathways. *Adv Cancer Res*, 88:53–99. [PubMed].
- [22]. Dudley JP. (2003). Tag, you're hit: retroviral insertions identify genes involved in cancer. *Trends Mol Med*, 9(2):43–5. [PubMed].
- [23]. Lund AH, Turner G, Trubetskoy A, et al. (2002). Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. *Nat Genet*, 32(1):160–5. [PubMed].
- [24]. Mikkers H, Allen J, Knipscheer P, et al. (2002). High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. *Nat Genet*, 32(1):153–9. [PubMed].
- [25]. Suzuki T, Shen H, Akagi K, et al. (2002). New genes involved in cancer identified by retroviral tagging. *Nat Genet*, 32(1):166–74. [PubMed].
- [26]. Yi Y, Jong Noh M, Hee Lee K. (2011). Current advances in retroviral gene therapy. *Curr Gene Ther*, 11(3):218–28. [PMC free article] [PubMed].
- [27]. Mergia A, Chari S, Kolson DL, et al. (2001). The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. *Virology*, 280(2):243–52. [PubMed].
- [28]. Rethwilm A. (2007). Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors. *Curr Gene Ther*, 7(4):261–71. [PubMed].
- [29]. Callahan ME, Switzer WM, Matthews AL, et al. (1999). Persistent Zoonotic Infection of a Human with Simian Foamy Virus in the Absence of an Intact orf-2 Accessory Gene. *J Virol*, 73(11):9619–24. [PMC free article] [PubMed].
- [30]. Heneine W, Switzer WM, Sandstrom P, et al. (1998). Identification of a human population infected with simian foamy viruses. *Nat Med*, 4(4):403–7.